Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-02-23

Clinical Trial Update: Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update showing the study of cetuximab (Erbitux) in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ERBITUX (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colorectal Neoplasms, Metastases, Neoplasm | Phase 2 | Status: COMPLETED